Beam Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Beam Therapeutics Inc. (BEAM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $20.20 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-04
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $19.52, a 5.34% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $18.53, a 8.55% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $17.07, a 43.48% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $30.20, a 34.48% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $17.53, a 2.34% increase from fiscal 2024.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $17.13, a 38.56% decline from fiscal 2023.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $27.88, a 31.77% decline from fiscal 2022.
- Beam Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $40.86, a 30.23% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.20 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $19.52 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $17.53 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $17.49 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $17.60 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $18.53 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $17.13 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $17.05 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $16.94 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $17.07 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $27.88 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $28.21 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $29.21 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $30.20 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $40.86 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $41.84 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $42.26 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $46.09 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $58.56 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $58.85 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $57.33 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $53.59 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $15.32 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $13.35 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $12.79 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $12.06 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $6.64 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |